Publicaciones científicas

Identification of COPD Patients at High Risk for Lung Cancer Mortality Using the COPD-LUCSS-DLCO

de-Torres JP (1), Marín JM (2), Casanova C (3), Pinto-Plata V (4), Divo M (4), Cote C (5), Celli BR (4), Zulueta JJ (6).
(1) Pulmonary Department, Clínica Universidad de Navarra, Pamplona, Spain.
(2) Pulmonary Department, Hospital Universitario Miguel Servet, Instituto Aragones Ciencias Salud and CIBER Enfermedades Respiratorias, Zaragoza, Spain.
(3) Pulmonary Department, Hospital Ntra Sra de Candelaria, Tenerife, Spain; Respiratory Research Unit, Hospital Ntra Sra de Candelaria, Tenerife, Spain.
(4) Pulmonary Department, Brigham and Women's Hospital, Harvard Medical School Boston, MA.
(5) Pulmonary and Critical Care Department, Bay Pines VA Medical Healthcare System, Bay Pines, FL.
(6) Pulmonary Department, Clínica Universidad de Navarra, Pamplona, Spain. 

Revista: Chest

Fecha: 01-abr-2016

Neumología

BACKGROUND:
The COPD-Lung Cancer Screening Score (COPD-LUCSS) is a tool designed to help identify patients with COPD with the highest risk of developing lung cancer (LC). The COPD-LUCSS includes the determination of radiological emphysema, a potential limitation for its implementation in clinical practice. The diffusing capacity for carbon monoxide (DLCO) is a surrogate marker of emphysema and correlates well with CT-determined emphysema.

OBJECTIVE:
To explore the use of the COPD-LUCSS using the DLCO instead of radiological emphysema, as a tool to identify patients with COPD at higher risk of LC death.

METHODS:
The Body Mass Index, Airflow Obstruction, Dyspnea, Exercise Performance international cohort database was analyzed. By logistic regression analysis, we confirmed that the other parameters included in the COPD-LUCSS (age > 60, pack-years > 60, BMI < 25) were independently associated with LC death.

We selected the best cutoff value for DLCO that independently predicted LC death. We then integrated the new COPD-LUCSS-DLCO assigning points to each parameter according to its hazard ratio value in the Cox regression model. The score ranges from 0 to 8 points.

RESULTS:
By regression analysis, age > 60, BMI <25 kg/m(2), pack-year history > 60, and DLCO < 60% were independently associated with LC diagnosis. Two COPD-LUCSS-DLCO risk categories were identified: low risk (scores 0-3) and high risk (scores 3.5-8). In comparison to patients at low risk, risk of death from LC increased 2.4-fold (95% CI, 2.0-2.7) in the high-risk category.

CONCLUSIONS:
The COPD-LUCSS using DLCO instead of CT-determined emphysema is a useful tool to identify patients with COPD at risk of LC death and may help in its implementation in clinical practice.

CITA DEL ARTÍCULO  Chest. 2016 Apr;149(4):936-42. doi: 10.1378/chest.15-1868. Epub 2016 Jan 12

tal vezLE INTERESE

¿QUÉ TECNOLOGÍA UTILIZAMOS?

La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

NUESTROS
PROFESIONALES

Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.

Imagen profesionales de la Clínica Universidad de Navarra

POR QUÉ VENIR
A LA CLÍNICA

Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.

Imagen del edificio de la Clínica Universidad de Navarra